Wall Street Zen Upgrades Neuphoria Therapeutics (NASDAQ:NEUP) to Hold

Neuphoria Therapeutics (NASDAQ:NEUP) was upgraded by equities research analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday.

A number of other research analysts also recently issued reports on NEUP. HC Wainwright downgraded shares of Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Price Performance

NEUP opened at $3.64 on Friday. The business’s 50-day moving average is $4.29 and its two-hundred day moving average is $4.39. Neuphoria Therapeutics has a 1 year low of $3.19 and a 1 year high of $21.40. The firm has a market capitalization of $19.66 million, a PE ratio of -0.33 and a beta of 0.74.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.47. As a group, sell-side analysts expect that Neuphoria Therapeutics will post -4.07 EPS for the current year.

Hedge Funds Weigh In On Neuphoria Therapeutics

Several hedge funds have recently modified their holdings of NEUP. AdvisorShares Investments LLC boosted its stake in Neuphoria Therapeutics by 15.8% in the 1st quarter. AdvisorShares Investments LLC now owns 155,367 shares of the company’s stock worth $632,000 after purchasing an additional 21,173 shares in the last quarter. Diadema Partners LP grew its position in Neuphoria Therapeutics by 133.1% during the 4th quarter. Diadema Partners LP now owns 50,000 shares of the company’s stock worth $194,000 after purchasing an additional 28,548 shares during the last quarter. Ikarian Capital LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter valued at approximately $184,000. ADAR1 Capital Management LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter valued at approximately $116,000. Finally, FNY Investment Advisers LLC acquired a new position in Neuphoria Therapeutics during the 4th quarter valued at approximately $102,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.